Increase decrease in sublicense percentage based on revenues.

No definition available.

Name:	BFRG_IncreaseDecreaseInSublicensePercentageBasedOnRevenues
Namespace Prefix:	BFRG_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

License initiation fee.

+ References

No definition available.

+ Details

Name:	BFRG_LicenseInitiationFee
Namespace Prefix:	BFRG_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Payments for licence fees after IPO.

+ References

No definition available.

+ Details

Name:	BFRG_PaymentsForLicenceFeesAfterIPO
Namespace Prefix:	BFRG_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of royalty on net sales.

+ References

No definition available.

+ Details

Name:	BFRG_PercentageOfRoyaltyOnNetSales
Namespace Prefix:	BFRG_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of warrant issued.

+ References

No definition available.

+ Details

Name:	BFRG_PercentageOfWarrantIssued
Namespace Prefix:	BFRG_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of sublicense.

+ References

No definition available.

+ Details

Name:	BFRG_SublicensePercentage
Namespace Prefix:	BFRG_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront licence fee.

+ References

No definition available.

+ Details

Name:	BFRG_UpfrontLicenceFee
Namespace Prefix:	BFRG_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cost of maintenance incurred and directly related to good produced and service rendered.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostMaintenance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_FiniteLivedPatentsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=BFRG_JHUAPLTechnologyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=BFRG_NewLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=BFRG_FromTwoThousandAndTwentyThreeThroughTwoThousandAndTwentySevenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentyTwoYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentyThreeYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentyFourYearAndBeyondMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_JulyTwoThousandTwentyThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentyFiveYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentySixYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentySevenYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentyFourYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=BFRG_InternallyDevelopmentDrugProjectsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=BFRG_OtherPartiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=BFRG_GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=BFRG_JohnsHopkinsUniversityMebendazoleLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=BFRG_JohnsHopkinsUniversityProdrugLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentyEightYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandTwentyNineYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=BFRG_TwoThousandThirtyYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Material Agreements (Details Narrative) - USD ($)	1 Months Ended					12 Months Ended
Material Agreements (Details Narrative) - USD ($)	May 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Feb. 28, 2022	Oct. 31, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2022
JHU - APL Technology License Agreement [Member]
Warrant issuance percentage					5.00%
Royalty percent					8.00%
Percentage of sublicense revenues					50.00%
Annual maintenance fee					$ 1,500
Royalty payments						$ 300,000	$ 80,000	$ 20,000
New License Agreement [Member]
Common stock issued			39,879
New License Agreement [Member] \| From 2023 through 2027 [Member]
License payments	$ 275,000
New License Agreement [Member] \| 2022 [Member]
Royalty payments								$ 30,000
New License Agreement [Member] \| 2023 [Member]
Royalty payments	60,000						80,000
New License Agreement [Member] \| 2024 and Beyond [Member]
Royalty payments						300,000
New License Agreement [Member] \| July 2023 [Member]
Royalty payments	75,000
New License Agreement [Member] \| 2025 [Member]
Royalty payments	75,000
New License Agreement [Member] \| 2026 [Member]
Royalty payments	75,000
New License Agreement [Member] \| 2027 [Member]
Royalty payments	$ 50,000
New License Agreement [Member] \| 2024 [Member]
Accrued royalty expenses						300,000
New License Agreement [Member] \| Maximum [Member]
Percentage of sublicense revenues			50.00%
New License Agreement [Member] \| Minimum [Member]
Sublicense fee based on revenue			25.00%
New License Agreement [Member] \| Internally Development Drug Projects [Member]
Royalty percent			3.00%
New License Agreement [Member] \| Other Parties [Member]
Royalty percent			8.00%
George Washington University - Beta2-spectrin siRNA License Agreement [Member]
Royalty percent									3.00%
Accrued royalty expenses						0
License initiation fee									$ 20,000
Johns Hopkins University - Mebendazole License Agreement [Member]
Royalty percent				3.50%
Accrued royalty expenses						20,000	10,000
Upfront licence fee				$ 250,000
License fee payment made prior to IPO				50,000
Annual minimum royalty payment after first commercial sale				250,000
Johns Hopkins University - Mebendazole License Agreement [Member] \| IPO [Member]
License fee payment made after IPO				200,000
Johns Hopkins University - Mebendazole License Agreement [Member] \| 2022 [Member]
Royalty payments				5,000
Johns Hopkins University - Mebendazole License Agreement [Member] \| 2023 [Member]
Royalty payments				10,000
Johns Hopkins University - Mebendazole License Agreement [Member] \| 2025 [Member]
Royalty payments				30,000
Johns Hopkins University - Mebendazole License Agreement [Member] \| 2026 [Member]
Royalty payments				50,000
Johns Hopkins University - Mebendazole License Agreement [Member] \| 2024 [Member]
Royalty payments				$ 20,000
Johns Hopkins University - Prodrug License Agreement [Member]
Royalty percent		4.00%
Accrued royalty expenses						$ 0	$ 0
Upfront licence fee		$ 100,000
Annual minimum royalty payment after first commercial sale		150,000
Johns Hopkins University - Prodrug License Agreement [Member] \| 2026 [Member]
Royalty payments		5,000
Johns Hopkins University - Prodrug License Agreement [Member] \| 2027 [Member]
Royalty payments		10,000
Johns Hopkins University - Prodrug License Agreement [Member] \| 2028 [Member]
Royalty payments		20,000
Johns Hopkins University - Prodrug License Agreement [Member] \| 2029 [Member]
Royalty payments		30,000
Johns Hopkins University - Prodrug License Agreement [Member] \| 2030 [Member]
Royalty payments		$ 50,000